Charlotte Kirby Charlotte Kirby

PhoreMost promotes Dr Neil Torbett to Chief Executive Officer

PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announces the promotion of Dr Neil Torbett to Chief Executive Officer, with immediate effect. Dr Torbett was previously the Company’s Chief Operating Officer. Founder and former CEO, Dr Chris Torrance will become Chair of the Board.

Read More
Charlotte Kirby Charlotte Kirby

Healx and Ovid Therapeutics enter strategic partnership

Ovid Therapeutics, a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, and Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, announces that Healx has secured from Ovid an exclusive option to license rights to develop and commercialize gaboxadol.

Read More
Charlotte Kirby Charlotte Kirby

Phico Therapeutics establishes Scientific Advisory Board

Phico Therapeutics Ltd (‘Phico’), a biotechnology company developing engineered phage technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, today announced that it has established a Science Advisory Board (SAB) to provide strategic scientific guidance to the Company.

Read More
Charlotte Kirby Charlotte Kirby

Eagle Genomics Selected for Catalonia-Based Initiative to Support Expansion into Spanish-Speaking Markets

Eagle Genomics, the Deep Tech platform business pioneering the application of network science to biology across the Food and Nutrition, Biopharma, Beauty and Personal Care, and AgBio industries, announced that it has been selected to participate in the Fast-Track Programme to Barcelona-Catalonia Life Science Hub (‘Programme’), Catalonia Trade & Investment’s initiative for UK firms looking to expand to Spanish-speaking markets.

Read More